AbCellera Biologics(NASDAQ) ABCL

AbCellera Biologics Inc. helps drug companies find natural antibodies to treat diseases. It uses an AI platform to search immune systems for new medicines. The firm works with partners to make drug discovery more efficient.

From Discovery to Development

• Internal Pipeline: Drug candidates like ABCL635 and ABCL575 developed for women's health and immunology; programs are managed through clinical trials.
• Partnered Discovery: Research services for companies like Eli Lilly and Company using a platform to find specific antibodies.
• Strategic Licensing: Access to Trianni mouse technology for partners to create human-like antibodies independently.
• Downstream Rights: Rights to receive milestone payments and royalties from 35 active programs as they progress toward commercial sales.

New Partnerships and Clinical Progress

• Secured a $56.0 million upfront payment from Jazz Pharmaceuticals PLC in June 2026 to develop next-generation antibodies.
• Signed a collaboration with Vertex Pharmaceuticals Inc. in July 2026 to research treatments for autoimmune diseases.
• Dosed the first patients in a Phase 2 clinical trial for its lead candidate, ABCL635, in January 2026.
• Completed construction of a clinical manufacturing facility in December 2025 to support internal drug production.
• Advanced two new candidates for oncology and autoimmunity into pre-clinical studies required for human testing in 2025.

Combining Data With Biology

The company integrates computer-driven analysis with biological research to explore natural immune systems more thoroughly than traditional methods. Its strategy combines internal drug development with a network of 35 partner-led programs to diversify its sources of future revenue.

Revenue and Research Spending

• Total revenue reached $4.1 million for the three-month period ended June 30, 2026, down 76% year over year.
• Net loss reached $55.4 million during the quarter ended June 30, 2026, compared to a net loss of $34.7 million in 2025.
• Total cash, cash equivalents, and marketable securities reached $540.1 million as of June 30, 2026.
• Research and development expenses reached $46.0 million for the quarter ended June 30, 2026, up 17% year over year.
• The company had 12 unique molecules in clinical trials as of June 30, 2026.

Bottom Line

AbCellera has evolved from a discovery platform provider into a clinical-stage firm with its own drug pipeline. This shift toward internal development alongside strategic partnerships provides multiple paths for long-term growth.